ArticlePsycho-oncology2025
Steroid-Induced Mental Disorders in Oncology Patients: A 10-Year Retrospective Case Series Review.
Article in Psycho-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Onco-anxiology: a proposal for an anxiety-focused, longitudinal framework within cancer care.Frontiers in psychology · 2026Article
- Prognostic value of emotional distress in advanced non-small cell lung cancer: a systematic review and meta-analysis.Frontiers in oncology · 2026Article
- Revisiting the use of steroids in oncology.Medical oncology (Northwood, London, England) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePatients with cancer are commonly prescribed corticosteroids for a variety of indications. Corticosteroids have long been known to affect mental state. Neuropsychiatric effects range from insomnia, cognitive impairment, and mood symptoms to psychosis and mania. In this study, we aimed to investigate the demographics, steroid exposure, referring indications, symptom profiles, and subsequent treatments of steroid-induced mental disorders in oncology patients.
methodsWe conducted a retrospective chart review of patients diagnosed with a steroid-induced mental disorder, as assessed by the psycho-oncology team in Cork University Hospital from 2626 referrals to the service between January 2010 to December 2019.
resultsIn total, 297 patients had a diagnosis of steroid-induced mental disorder (11% of referrals). 60.6% were female and mean age ± standard deviation (SD) was 57.5 ± 12.9 years. Breast cancer was the most frequent malignancy among females. Haematological cancer was the most frequent among males and the second most frequent among females. The most commonly prescribed steroid was dexamethasone, followed by prednisolone. The median (interquartile range [IQR]) cumulative weekly prednisolone equivalent dose was 186 mg (125-350 mg), with a median (IQR) duration of steroid exposure before symptom onset of 14 (6-47) days. The most frequently recorded symptoms following psychiatric assessment included insomnia, anxiety, and irritability. Psychotropics were commenced in n = 174 (74%) patients, with antipsychotics prescribed to 62.1%. A watchful wait approach was adopted for 25.5% of the patients. 90.2% (n = 185/205) of the patients experienced either complete or partial resolution of the symptoms at their first clinical review.
conclusionsSteroid-induced mental disorders can cause significant comorbidity in patients receiving cancer treatment. The most common symptoms recorded during assessment included insomnia, anxiety, and irritability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.